JPRN-UMIN000016754
Completed
未知
The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan. - The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy.
Saitama Medical Center, Saitama Medical University0 sites50 target enrollmentApril 1, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- diabetic nephropathy in type 2 diabetes mellitus
- Sponsor
- Saitama Medical Center, Saitama Medical University
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patient with a severe ketotic diabetic coma or precoma. 2\)Patient with severe infectious disease, before and after operation, and a serious injury. 3\)End\-stage renal failure patients with severe renal impairment (eGFR \<30mL / min) or during dialysis 4\)A pregnant woman or woman who may be pregnant. 5\)Patient with a past history of hypersensitivity for Ipragliflozin. 6\)Patients who isn't obtained the consent in writing 7\)Patient who is considered to be inappropriate by the chief physician.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndromeType 2 diabetesJPRN-UMIN000045226Akishima Clinic16
Not yet recruiting
Not Applicable
Influence of SGLT2 inhibitors on the efficiency of peritoneal dialysisChronic kidney disease under peritoneal dialysisJPRN-UMIN000049848International University of Health and Welfare10
Not yet recruiting
Not Applicable
Observational Study of the effect of SGLT2 inhibitor on Glycemic Control Indicesdiabetes mellitusJPRN-UMIN000050228agoya University4,250
Recruiting
Not Applicable
Influence of SGLT2 inhibitor on myocardial fatty acid metabolismtype 2 diabetesJPRN-jRCT1041190002Kumazaki Setsuo40
Active, not recruiting
Phase 1
The REFORM TrialType 2 diabetes and Heart FailureTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2014-002742-42-GBniversity of Dundee/ NHS Tayside56